The Experts below are selected from a list of 22599 Experts worldwide ranked by ideXlab platform

James E. Mitchell - One of the best experts on this subject based on the ideXlab platform.

  • Are the Criterion B Binge-Eating symptoms interchangeable in understanding Binge-Eating severity? An item response theory analysis.
    The International journal of eating disorders, 2020
    Co-Authors: Brianne Richson, Ross D. Crosby, Carol B. Peterson, Scott J. Crow, Kelsie T. Forbush, Katherine Schaumberg, James E. Mitchell
    Abstract:

    OBJECTIVE The Criterion B Binge-Eating symptoms represent five symptoms associated with Binge Eating. Any three out of five symptoms can be used to meet Criterion B. However, Criterion B symptoms may not be interchangeable in terms of how Binge-Eating severity is associated with each symptom. Item response theory (IRT) can test how endorsing each symptom relates to the overall level (i.e., severity) of Binge-Eating measured by Criterion B. We used IRT to identify (a) how each Criterion B symptom corresponded with Binge-Eating severity in a transdiagnostic Binge-Eating sample and (b) how well each symptom differentiated individuals with differing levels of severity. METHOD Participants (N = 219) were adults (80.8% female) with a current ED that included objective Binge-Eating episodes assessed via semi-structured interview. A two-parameter logistic IRT model evaluated how endorsement of each Criterion B symptom corresponded with the level of latent Binge-Eating severity. RESULTS "Eating large amounts when not hungry" and "Eating alone" reflected the highest Binge-Eating severity. "Eating alone" was the best discriminator across different Binge-Eating severity levels, whereas "uncomfortably full" was the poorest discriminator across Binge-Eating severity levels. DISCUSSION Criterion B symptoms were not interchangeable in terms of what level of Binge-Eating severity corresponded with symptom endorsement. "Eating large amounts when not hungry" or "Eating alone" may signify elevated Binge-Eating severity, whereas "uncomfortably full" and "feeling disgusted/depressed/guilty" were not necessarily indicative of elevated severity. Results suggested that Criterion B may need to be revised to eliminate symptoms that are redundant with other Binge-Eating diagnostic criteria.

  • lisdexamfetamine dimesylate effects on Binge Eating behaviour and obsessive compulsive and impulsive features in adults with Binge Eating disorder
    European Eating Disorders Review, 2016
    Co-Authors: Susan L. Mcelroy, James E. Mitchell, Denise E. Wilfley, Maria Gasior, Celeste M Ferreiracornwell, Michael Mckay, Jiannong Wang, Timothy Whitaker, James I. Hudson
    Abstract:

    In a published 11-week, placebo-controlled trial, 50 and 70 mg/d lisdexamfetamine dimesylate (LDX), but not 30 mg/d LDX, significantly reduced Binge Eating days (primary endpoint) in adults with Binge Eating disorder (BED). This report provides descriptions of LDX effects on secondary endpoints (Binge Eating Scale [BES]; Three-Factor Eating Questionnaire [TFEQ]; Yale–Brown Obsessive Compulsive Scale modified for Binge Eating [Y-BOCS-BE]; and the Barratt Impulsiveness Scale, version 11 [BIS-11]) from that study. Week 11 least squares mean treatment differences favoured all LDX doses over placebo on the BES (p ≤ 0.03), TFEQ Disinhibition and Hunger subscales (all p < 0.05), and Y-BOCS-BE total, obsessive, and compulsive scales (all p ≤ 0.02) and on BIS-11 total score at 70 mg/d LDX (p = 0.015) and the TFEQ Cognitive Restraint subscale at 30 and 70 mg/d LDX (both p<0.05). These findings indicate that LDX decreased global Binge Eating severity and obsessive–compulsive and impulsive features of BED in addition to Binge Eating days. Copyright © 2015 John Wiley & Sons, Ltd and Eating Disorders Association.

  • lisdexamfetamine dimesylate effects on Binge Eating behaviour and obsessive compulsive and impulsive features in adults with Binge Eating disorder
    European Eating Disorders Review, 2016
    Co-Authors: Susan L. Mcelroy, James E. Mitchell, Denise E. Wilfley, Maria Gasior, Celeste M Ferreiracornwell, Michael Mckay, Jiannong Wang, Timothy Whitaker, James I. Hudson
    Abstract:

    In a published 11-week, placebo-controlled trial, 50 and 70 mg/d lisdexamfetamine dimesylate (LDX), but not 30 mg/d LDX, significantly reduced Binge Eating days (primary endpoint) in adults with Binge Eating disorder (BED). This report provides descriptions of LDX effects on secondary endpoints (Binge Eating Scale [BES]; Three-Factor Eating Questionnaire [TFEQ]; Yale-Brown Obsessive Compulsive Scale modified for Binge Eating [Y-BOCS-BE]; and the Barratt Impulsiveness Scale, version 11 [BIS-11]) from that study. Week 11 least squares mean treatment differences favoured all LDX doses over placebo on the BES (p ≤ 0.03), TFEQ Disinhibition and Hunger subscales (all p < 0.05), and Y-BOCS-BE total, obsessive, and compulsive scales (all p ≤ 0.02) and on BIS-11 total score at 70 mg/d LDX (p = 0.015) and the TFEQ Cognitive Restraint subscale at 30 and 70 mg/d LDX (both p < 0.05). These findings indicate that LDX decreased global Binge Eating severity and obsessive-compulsive and impulsive features of BED in addition to Binge Eating days.

  • Lisdexamfetamine Dimesylate Effects on Binge Eating Behaviour and Obsessive–Compulsive and Impulsive Features in Adults with Binge Eating Disorder
    European eating disorders review : the journal of the Eating Disorders Association, 2015
    Co-Authors: Susan L. Mcelroy, James E. Mitchell, Denise E. Wilfley, Maria Gasior, Michael Mckay, Jiannong Wang, Timothy Whitaker, M. Celeste Ferreira-cornwell, James I. Hudson
    Abstract:

    In a published 11-week, placebo-controlled trial, 50 and 70 mg/d lisdexamfetamine dimesylate (LDX), but not 30 mg/d LDX, significantly reduced Binge Eating days (primary endpoint) in adults with Binge Eating disorder (BED). This report provides descriptions of LDX effects on secondary endpoints (Binge Eating Scale [BES]; Three-Factor Eating Questionnaire [TFEQ]; Yale-Brown Obsessive Compulsive Scale modified for Binge Eating [Y-BOCS-BE]; and the Barratt Impulsiveness Scale, version 11 [BIS-11]) from that study. Week 11 least squares mean treatment differences favoured all LDX doses over placebo on the BES (p ≤ 0.03), TFEQ Disinhibition and Hunger subscales (all p < 0.05), and Y-BOCS-BE total, obsessive, and compulsive scales (all p ≤ 0.02) and on BIS-11 total score at 70 mg/d LDX (p = 0.015) and the TFEQ Cognitive Restraint subscale at 30 and 70 mg/d LDX (both p < 0.05). These findings indicate that LDX decreased global Binge Eating severity and obsessive-compulsive and impulsive features of BED in addition to Binge Eating days.

  • Examining duration of Binge Eating episodes in Binge Eating disorder.
    The International journal of eating disorders, 2013
    Co-Authors: Deanna Schreiber-gregory, Jason M. Lavender, Scott G. Engel, Steve Wonderlich, Ross D. Crosby, Carol B. Peterson, Heather Simonich, Scott J. Crow, Nora Durkin, James E. Mitchell
    Abstract:

    Binge Eating Disorder (BED), originally introduced as a provisional Eating disorder diagnosis in the appendix of the 4th edition of the Diagnostic and Statistical Manual of Mental Disorders (DSM-IV) [1], is now included as a full diagnostic entity in the DSM-5 [2]. According to the DSM-5 criteria, a Binge Eating episode is characterized by: (a) consuming a significantly large amount of food in a discrete period of time (e.g., within two hours) compared to what most others would eat under similar circumstances; and (b) the presence of a subjective sense of loss of control over Eating. Although this definition of Binge Eating specifies a broad duration criterion by example (i.e., occurring within a discrete time period of two hours or less), there is little information regarding Binge Eating episode duration and whether duration of Binges is associated with clinically relevant variables (e.g., severity of Eating disorder psychopathology or co-occurring affective disturbance), particularly in BED. Early research on Binge Eating behavior focused on patients with bulimia nervosa (BN). For example, Mitchell, Pyle, and Eckert [3] examined characteristics of Binge Eating based on self-reports in patients with BN, finding a mean Binge Eating episode duration of slightly more than one hour, with a range from 15 minutes to 8 hours. Similarly, Mitchell and Laine [4] examined Binge Eating characteristics in a small sample of normal-weight patients with BN over a 24-hour period. The average Binge Eating episode duration was approximately one hour, and results suggested that participants had noticeably abnormal Eating patterns (i.e., type of food consumed and order in which the type of food was consumed) during both normal and Binge Eating episodes. More recently, a study by Kissileff, Zimmerli, Torres, Devlin, and Walsh [5] examined caloric intake among normal controls and individuals with BN, who were asked to Binge eat a yogurt shake served at either a slow or fast rate in a structured laboratory setting. Normal controls consumed more calories during the fast condition than in the slow condition. As expected, individuals with BN consumed more on average than normal controls, but calories consumed did not differ across the fast and slow conditions among BN participants. While a small amount of empirical study has examined differences between BED and BN [6], little is actually known about differences in Binge Eating between these clinical groups. Better understanding of the clinical features of Binge Eating in both BN and BED, and the differences between these features, may prove informative regarding the precipitants and maintaining factors associated with Binge Eating in both clinical populations. Recent studies have examined features and correlates of Binge Eating and other Eating behavior in BED (e.g., meal size and BMI [7]; hunger and fullness [8]). Research on Binge Eating in laboratory settings has consistently revealed that individuals with BED consume significantly more calories than individuals without BED, regardless of whether or not participants are explicitly instructed to Binge eat [9]. However, other features of Binge Eating in BED, such as duration of Binge Eating episodes, have not been examined in detail. Empirical findings regarding the duration of Binge Eating episodes in BED are particularly lacking. Considering this gap in the existing literature, there is a need for additional data on this feature of Binge Eating, particularly given that this criterion is included within the diagnostic definition of what constitutes an episode of Binge Eating. The primary goal of this investigation was to further examine and clarify Binge Eating in individuals with BED, with a particular emphasis on the duration of Binge Eating episodes. Two studies were conducted with separate BED samples. The first utilized self-report data collected via semi-structured interviews and questionnaires and allowed a comparison of individuals with self-reported short versus long average Binge Eating episode durations. The second utilized ecological momentary assessment (EMA), an assessment methodology used in numerous studies of Binge Eating [10-14], to examine the mean duration and temporal patterns (i.e., across the hours of the day, and across the days of the week) of Binge Eating in the natural environment.

Susan L. Mcelroy - One of the best experts on this subject based on the ideXlab platform.

  • Medication for Binge Eating
    Binge Eating, 2020
    Co-Authors: Susan L. Mcelroy, Anna I. Guerdjikova, Nicole Mori, Francisco Romo-nava
    Abstract:

    This chapter reviews the use of medications in the treatment of individuals with bulimia nervosa (BN) and Binge-Eating disorder (BED), the two mental disorders defined by the presence of Binge Eating. Drug classes evaluated include antidepressants, stimulants, and other medications for attention-deficit/hyperactivity disorder (ADHD), antiepileptic drugs, opioid antagonists, and weight loss agents, among others. The only two drugs with regulatory approval for Binge Eating are fluoxetine for BN and lisdexamfetamine for BED. Other available drugs with established efficacy in BN and BED include antidepressants (especially selective serotonin reuptake inhibitors) and the antiepileptic topiramate, though the efficacy of these compounds is modest at best. We found no evidence of a drug developed specifically for the treatment of individuals with BN or BED. Importantly, until drugs are developed specifically for Eating disorders with Binge Eating, drugs developed for other conditions that are centrally acting and associated with beneficial psychotropic effects or reduced appetite or weight loss might be considered for repurposing in BN and BED.

  • lisdexamfetamine dimesylate effects on Binge Eating behaviour and obsessive compulsive and impulsive features in adults with Binge Eating disorder
    European Eating Disorders Review, 2016
    Co-Authors: Susan L. Mcelroy, James E. Mitchell, Denise E. Wilfley, Maria Gasior, Celeste M Ferreiracornwell, Michael Mckay, Jiannong Wang, Timothy Whitaker, James I. Hudson
    Abstract:

    In a published 11-week, placebo-controlled trial, 50 and 70 mg/d lisdexamfetamine dimesylate (LDX), but not 30 mg/d LDX, significantly reduced Binge Eating days (primary endpoint) in adults with Binge Eating disorder (BED). This report provides descriptions of LDX effects on secondary endpoints (Binge Eating Scale [BES]; Three-Factor Eating Questionnaire [TFEQ]; Yale–Brown Obsessive Compulsive Scale modified for Binge Eating [Y-BOCS-BE]; and the Barratt Impulsiveness Scale, version 11 [BIS-11]) from that study. Week 11 least squares mean treatment differences favoured all LDX doses over placebo on the BES (p ≤ 0.03), TFEQ Disinhibition and Hunger subscales (all p < 0.05), and Y-BOCS-BE total, obsessive, and compulsive scales (all p ≤ 0.02) and on BIS-11 total score at 70 mg/d LDX (p = 0.015) and the TFEQ Cognitive Restraint subscale at 30 and 70 mg/d LDX (both p<0.05). These findings indicate that LDX decreased global Binge Eating severity and obsessive–compulsive and impulsive features of BED in addition to Binge Eating days. Copyright © 2015 John Wiley & Sons, Ltd and Eating Disorders Association.

  • lisdexamfetamine dimesylate effects on Binge Eating behaviour and obsessive compulsive and impulsive features in adults with Binge Eating disorder
    European Eating Disorders Review, 2016
    Co-Authors: Susan L. Mcelroy, James E. Mitchell, Denise E. Wilfley, Maria Gasior, Celeste M Ferreiracornwell, Michael Mckay, Jiannong Wang, Timothy Whitaker, James I. Hudson
    Abstract:

    In a published 11-week, placebo-controlled trial, 50 and 70 mg/d lisdexamfetamine dimesylate (LDX), but not 30 mg/d LDX, significantly reduced Binge Eating days (primary endpoint) in adults with Binge Eating disorder (BED). This report provides descriptions of LDX effects on secondary endpoints (Binge Eating Scale [BES]; Three-Factor Eating Questionnaire [TFEQ]; Yale-Brown Obsessive Compulsive Scale modified for Binge Eating [Y-BOCS-BE]; and the Barratt Impulsiveness Scale, version 11 [BIS-11]) from that study. Week 11 least squares mean treatment differences favoured all LDX doses over placebo on the BES (p ≤ 0.03), TFEQ Disinhibition and Hunger subscales (all p < 0.05), and Y-BOCS-BE total, obsessive, and compulsive scales (all p ≤ 0.02) and on BIS-11 total score at 70 mg/d LDX (p = 0.015) and the TFEQ Cognitive Restraint subscale at 30 and 70 mg/d LDX (both p < 0.05). These findings indicate that LDX decreased global Binge Eating severity and obsessive-compulsive and impulsive features of BED in addition to Binge Eating days.

  • Lisdexamfetamine Dimesylate Effects on Binge Eating Behaviour and Obsessive–Compulsive and Impulsive Features in Adults with Binge Eating Disorder
    European eating disorders review : the journal of the Eating Disorders Association, 2015
    Co-Authors: Susan L. Mcelroy, James E. Mitchell, Denise E. Wilfley, Maria Gasior, Michael Mckay, Jiannong Wang, Timothy Whitaker, M. Celeste Ferreira-cornwell, James I. Hudson
    Abstract:

    In a published 11-week, placebo-controlled trial, 50 and 70 mg/d lisdexamfetamine dimesylate (LDX), but not 30 mg/d LDX, significantly reduced Binge Eating days (primary endpoint) in adults with Binge Eating disorder (BED). This report provides descriptions of LDX effects on secondary endpoints (Binge Eating Scale [BES]; Three-Factor Eating Questionnaire [TFEQ]; Yale-Brown Obsessive Compulsive Scale modified for Binge Eating [Y-BOCS-BE]; and the Barratt Impulsiveness Scale, version 11 [BIS-11]) from that study. Week 11 least squares mean treatment differences favoured all LDX doses over placebo on the BES (p ≤ 0.03), TFEQ Disinhibition and Hunger subscales (all p < 0.05), and Y-BOCS-BE total, obsessive, and compulsive scales (all p ≤ 0.02) and on BIS-11 total score at 70 mg/d LDX (p = 0.015) and the TFEQ Cognitive Restraint subscale at 30 and 70 mg/d LDX (both p < 0.05). These findings indicate that LDX decreased global Binge Eating severity and obsessive-compulsive and impulsive features of BED in addition to Binge Eating days.

  • Eating Disorders: Binge Eating
    2014
    Co-Authors: Susan L. Mcelroy, Anna I. Guerdjikova
    Abstract:

    Binge Eating is the consumption of an abnormally large amount of food in a discrete period of time accompanied by a sense of loss of control. Binge Eating is a core defining feature of two Eating disorders: bulimia nervosa (BN) and Binge-Eating disorder (BED). BN is further defined by inappropriate compensatory weight loss behaviors (e.g., self-induced vomiting) and excessive concern for shape and weight. By contrast, for BED, Binge Eating must be associated with other indicators of loss of control and distress, but not with the inappropriate compensatory weight loss behaviors of BN. Of note, Binge Eating may also occur in anorexia nervosa (AN), but is not required for its diagnosis.

James I. Hudson - One of the best experts on this subject based on the ideXlab platform.

  • lisdexamfetamine dimesylate effects on Binge Eating behaviour and obsessive compulsive and impulsive features in adults with Binge Eating disorder
    European Eating Disorders Review, 2016
    Co-Authors: Susan L. Mcelroy, James E. Mitchell, Denise E. Wilfley, Maria Gasior, Celeste M Ferreiracornwell, Michael Mckay, Jiannong Wang, Timothy Whitaker, James I. Hudson
    Abstract:

    In a published 11-week, placebo-controlled trial, 50 and 70 mg/d lisdexamfetamine dimesylate (LDX), but not 30 mg/d LDX, significantly reduced Binge Eating days (primary endpoint) in adults with Binge Eating disorder (BED). This report provides descriptions of LDX effects on secondary endpoints (Binge Eating Scale [BES]; Three-Factor Eating Questionnaire [TFEQ]; Yale–Brown Obsessive Compulsive Scale modified for Binge Eating [Y-BOCS-BE]; and the Barratt Impulsiveness Scale, version 11 [BIS-11]) from that study. Week 11 least squares mean treatment differences favoured all LDX doses over placebo on the BES (p ≤ 0.03), TFEQ Disinhibition and Hunger subscales (all p < 0.05), and Y-BOCS-BE total, obsessive, and compulsive scales (all p ≤ 0.02) and on BIS-11 total score at 70 mg/d LDX (p = 0.015) and the TFEQ Cognitive Restraint subscale at 30 and 70 mg/d LDX (both p<0.05). These findings indicate that LDX decreased global Binge Eating severity and obsessive–compulsive and impulsive features of BED in addition to Binge Eating days. Copyright © 2015 John Wiley & Sons, Ltd and Eating Disorders Association.

  • lisdexamfetamine dimesylate effects on Binge Eating behaviour and obsessive compulsive and impulsive features in adults with Binge Eating disorder
    European Eating Disorders Review, 2016
    Co-Authors: Susan L. Mcelroy, James E. Mitchell, Denise E. Wilfley, Maria Gasior, Celeste M Ferreiracornwell, Michael Mckay, Jiannong Wang, Timothy Whitaker, James I. Hudson
    Abstract:

    In a published 11-week, placebo-controlled trial, 50 and 70 mg/d lisdexamfetamine dimesylate (LDX), but not 30 mg/d LDX, significantly reduced Binge Eating days (primary endpoint) in adults with Binge Eating disorder (BED). This report provides descriptions of LDX effects on secondary endpoints (Binge Eating Scale [BES]; Three-Factor Eating Questionnaire [TFEQ]; Yale-Brown Obsessive Compulsive Scale modified for Binge Eating [Y-BOCS-BE]; and the Barratt Impulsiveness Scale, version 11 [BIS-11]) from that study. Week 11 least squares mean treatment differences favoured all LDX doses over placebo on the BES (p ≤ 0.03), TFEQ Disinhibition and Hunger subscales (all p < 0.05), and Y-BOCS-BE total, obsessive, and compulsive scales (all p ≤ 0.02) and on BIS-11 total score at 70 mg/d LDX (p = 0.015) and the TFEQ Cognitive Restraint subscale at 30 and 70 mg/d LDX (both p < 0.05). These findings indicate that LDX decreased global Binge Eating severity and obsessive-compulsive and impulsive features of BED in addition to Binge Eating days.

  • Lisdexamfetamine Dimesylate Effects on Binge Eating Behaviour and Obsessive–Compulsive and Impulsive Features in Adults with Binge Eating Disorder
    European eating disorders review : the journal of the Eating Disorders Association, 2015
    Co-Authors: Susan L. Mcelroy, James E. Mitchell, Denise E. Wilfley, Maria Gasior, Michael Mckay, Jiannong Wang, Timothy Whitaker, M. Celeste Ferreira-cornwell, James I. Hudson
    Abstract:

    In a published 11-week, placebo-controlled trial, 50 and 70 mg/d lisdexamfetamine dimesylate (LDX), but not 30 mg/d LDX, significantly reduced Binge Eating days (primary endpoint) in adults with Binge Eating disorder (BED). This report provides descriptions of LDX effects on secondary endpoints (Binge Eating Scale [BES]; Three-Factor Eating Questionnaire [TFEQ]; Yale-Brown Obsessive Compulsive Scale modified for Binge Eating [Y-BOCS-BE]; and the Barratt Impulsiveness Scale, version 11 [BIS-11]) from that study. Week 11 least squares mean treatment differences favoured all LDX doses over placebo on the BES (p ≤ 0.03), TFEQ Disinhibition and Hunger subscales (all p < 0.05), and Y-BOCS-BE total, obsessive, and compulsive scales (all p ≤ 0.02) and on BIS-11 total score at 70 mg/d LDX (p = 0.015) and the TFEQ Cognitive Restraint subscale at 30 and 70 mg/d LDX (both p < 0.05). These findings indicate that LDX decreased global Binge Eating severity and obsessive-compulsive and impulsive features of BED in addition to Binge Eating days.

  • Binge Eating Disorder: A Stable Syndrome
    The American journal of psychiatry, 2006
    Co-Authors: Harrison G. Pope, Scott J. Crow, Cynthia M. Bulik, Susan L. Mcelroy, Justine K. Lalonde, Lindsay J. Pindyck, Timothy Walsh, Norman E. Rosenthal, James I. Hudson
    Abstract:

    Objective: This study assessed the stability of Binge Eating disorder in a community sample. Method: The authors interviewed 888 first-degree relatives of 300 overweight or obese probands (150 with Binge Eating disorder and 150 with no lifetime Eating disorder) who were recruited during a family study. They compared the total duration of illness among relatives with lifetime diagnoses of Binge Eating disorder (N=131), bulimia nervosa (N=17), and anorexia nervosa (N=18). Results: The mean lifetime duration of Binge Eating disorder was 14.4 years (SD=13.9), significantly longer than for either bulimia nervosa (mean=5.8 years, SD=9.1) or anorexia nervosa (mean=5.9 years, SD=7.4). These differences changed little when analysis was restricted to female relatives or to relatives of the probands with no lifetime Eating disorder. Conclusions: These findings suggest that Binge Eating disorder is at least as chronic as the well-validated disorders anorexia nervosa and bulimia nervosa and likely represents a stable ...

Kelly L Klump - One of the best experts on this subject based on the ideXlab platform.

  • Differential strain vulnerability to Binge Eating behaviors in rats.
    Physiology & behavior, 2014
    Co-Authors: Britny A. Hildebrandt, Sarah E Racine, Kelly L Klump, Cheryl L. Sisk
    Abstract:

    Abstract Binge Eating is a significantly heritable phenotype, but efforts to detect specific risk genes have fallen short. Identification of animal strain differences in risk for Binge Eating could highlight genetic differences across individuals of the same species that can be exploited in future animal and molecular genetic research. The current study aimed to explore strain differences in risk for Binge Eating in Sprague–Dawley versus Wistar female rats using the Binge Eating Resistant/Binge Eating Prone model. A sample of male Sprague–Dawley rats, a known low-risk group for Binge Eating, was included as a comparison group. A total of 83 rats (23 Wistar females, 30 Sprague–Dawley females, 30 Sprague–Dawley males) completed a protocol of intermittently administered, palatable food. Binge Eating prone (BEP) and Binge Eating resistant (BER) rats were identified using a tertile approach. Sprague–Dawley female rats consumed the highest amount of palatable food and were more likely to be classified as BEP compared to Wistar female and Sprague–Dawley male rats. Wistar female rats were not significantly different from Sprague–Dawley male rats in their palatable food intake and tendency to be classified as BER rather than BEP. Sprague–Dawley female rats appear to be a particularly vulnerable genotype for Binge Eating. Comparisons between this group and others could help identify specific genetic/biological factors that differentiate it from lower risk groups. The reward system, linked to Binge Eating in humans, is a possible candidate to explore. Strain differences in the reward system could help increase understanding of individual differences in risk for Binge Eating in humans.

  • dietary restraint moderates genetic risk for Binge Eating
    Journal of Abnormal Psychology, 2011
    Co-Authors: Sarah E Racine, Alexandra S Burt, William G Iacono, Matt Mcgue, Kelly L Klump
    Abstract:

    Dietary restraint is a prospective risk factor for the development of Binge Eating and bulimia nervosa. Although many women engage in dietary restraint, relatively few develop Binge Eating. Dietary restraint may only increase susceptibility for Binge Eating in individuals who are at genetic risk. Specifically, dietary restraint may be a behavioral “exposure” factor that activates genetic predispositions for Binge Eating. We investigated this possibility in 1,678 young adolescent and adult same-sex female twins from the Minnesota Twin Family Study and the Michigan State University Twin Registry. Twin moderation models were used to examine whether levels of dietary restraint moderate genetic and environmental influences on Binge Eating. Results indicated that genetic and non-shared environmental factors for Binge Eating increased at higher levels of dietary restraint. Importantly, these effects were present after controlling for age, body mass index, and genetic and environmental overlap among dietary restraint and Binge Eating. Results suggest that dietary restraint may be most important for individuals at genetic risk for Binge Eating, and the combination of these factors could enhance individual differences in risk for Binge Eating.

Denise E. Wilfley - One of the best experts on this subject based on the ideXlab platform.

  • Psychotherapy for Binge Eating
    Binge Eating, 2020
    Co-Authors: Mary Katherine Ray, Anne Claire Grammer, Genevieve Davison, Ellen E. Fitzsimmons-craft, Denise E. Wilfley
    Abstract:

    There are many types of psychotherapy used to treat Binge Eating in bulimia nervosa (BN) and Binge-Eating disorder (BED). Some of the most common psychotherapies include cognitive behavioral therapy (CBT), interpersonal psychotherapy (IPT), behavioral weight-loss treatment (BWL), third-wave therapies (e.g., dialectical behavior therapy, DBT), and family-based therapy (FBT). This chapter was designed to review the empirical evidence for each of these interventions to treat Binge Eating in both BN and BED. The chapter highlights the most well-supported psychotherapies and briefly discusses promising psychotherapies that are emerging in the field. Given the vast differences in Binge Eating treatment for adults and youth, the chapter discusses each population separately to provide the most comprehensive overview of the literature. The chapter also discusses the efficacy of these psychotherapies to address comorbidities that are often associated with Binge-Eating-related disorders (e.g., depression) and reviews future directions of the field.

  • lisdexamfetamine dimesylate effects on Binge Eating behaviour and obsessive compulsive and impulsive features in adults with Binge Eating disorder
    European Eating Disorders Review, 2016
    Co-Authors: Susan L. Mcelroy, James E. Mitchell, Denise E. Wilfley, Maria Gasior, Celeste M Ferreiracornwell, Michael Mckay, Jiannong Wang, Timothy Whitaker, James I. Hudson
    Abstract:

    In a published 11-week, placebo-controlled trial, 50 and 70 mg/d lisdexamfetamine dimesylate (LDX), but not 30 mg/d LDX, significantly reduced Binge Eating days (primary endpoint) in adults with Binge Eating disorder (BED). This report provides descriptions of LDX effects on secondary endpoints (Binge Eating Scale [BES]; Three-Factor Eating Questionnaire [TFEQ]; Yale–Brown Obsessive Compulsive Scale modified for Binge Eating [Y-BOCS-BE]; and the Barratt Impulsiveness Scale, version 11 [BIS-11]) from that study. Week 11 least squares mean treatment differences favoured all LDX doses over placebo on the BES (p ≤ 0.03), TFEQ Disinhibition and Hunger subscales (all p < 0.05), and Y-BOCS-BE total, obsessive, and compulsive scales (all p ≤ 0.02) and on BIS-11 total score at 70 mg/d LDX (p = 0.015) and the TFEQ Cognitive Restraint subscale at 30 and 70 mg/d LDX (both p<0.05). These findings indicate that LDX decreased global Binge Eating severity and obsessive–compulsive and impulsive features of BED in addition to Binge Eating days. Copyright © 2015 John Wiley & Sons, Ltd and Eating Disorders Association.

  • lisdexamfetamine dimesylate effects on Binge Eating behaviour and obsessive compulsive and impulsive features in adults with Binge Eating disorder
    European Eating Disorders Review, 2016
    Co-Authors: Susan L. Mcelroy, James E. Mitchell, Denise E. Wilfley, Maria Gasior, Celeste M Ferreiracornwell, Michael Mckay, Jiannong Wang, Timothy Whitaker, James I. Hudson
    Abstract:

    In a published 11-week, placebo-controlled trial, 50 and 70 mg/d lisdexamfetamine dimesylate (LDX), but not 30 mg/d LDX, significantly reduced Binge Eating days (primary endpoint) in adults with Binge Eating disorder (BED). This report provides descriptions of LDX effects on secondary endpoints (Binge Eating Scale [BES]; Three-Factor Eating Questionnaire [TFEQ]; Yale-Brown Obsessive Compulsive Scale modified for Binge Eating [Y-BOCS-BE]; and the Barratt Impulsiveness Scale, version 11 [BIS-11]) from that study. Week 11 least squares mean treatment differences favoured all LDX doses over placebo on the BES (p ≤ 0.03), TFEQ Disinhibition and Hunger subscales (all p < 0.05), and Y-BOCS-BE total, obsessive, and compulsive scales (all p ≤ 0.02) and on BIS-11 total score at 70 mg/d LDX (p = 0.015) and the TFEQ Cognitive Restraint subscale at 30 and 70 mg/d LDX (both p < 0.05). These findings indicate that LDX decreased global Binge Eating severity and obsessive-compulsive and impulsive features of BED in addition to Binge Eating days.

  • Lisdexamfetamine Dimesylate Effects on Binge Eating Behaviour and Obsessive–Compulsive and Impulsive Features in Adults with Binge Eating Disorder
    European eating disorders review : the journal of the Eating Disorders Association, 2015
    Co-Authors: Susan L. Mcelroy, James E. Mitchell, Denise E. Wilfley, Maria Gasior, Michael Mckay, Jiannong Wang, Timothy Whitaker, M. Celeste Ferreira-cornwell, James I. Hudson
    Abstract:

    In a published 11-week, placebo-controlled trial, 50 and 70 mg/d lisdexamfetamine dimesylate (LDX), but not 30 mg/d LDX, significantly reduced Binge Eating days (primary endpoint) in adults with Binge Eating disorder (BED). This report provides descriptions of LDX effects on secondary endpoints (Binge Eating Scale [BES]; Three-Factor Eating Questionnaire [TFEQ]; Yale-Brown Obsessive Compulsive Scale modified for Binge Eating [Y-BOCS-BE]; and the Barratt Impulsiveness Scale, version 11 [BIS-11]) from that study. Week 11 least squares mean treatment differences favoured all LDX doses over placebo on the BES (p ≤ 0.03), TFEQ Disinhibition and Hunger subscales (all p < 0.05), and Y-BOCS-BE total, obsessive, and compulsive scales (all p ≤ 0.02) and on BIS-11 total score at 70 mg/d LDX (p = 0.015) and the TFEQ Cognitive Restraint subscale at 30 and 70 mg/d LDX (both p < 0.05). These findings indicate that LDX decreased global Binge Eating severity and obsessive-compulsive and impulsive features of BED in addition to Binge Eating days.

  • psychological treatments of Binge Eating disorder
    Archives of General Psychiatry, 2010
    Co-Authors: Terence G Wilson, Denise E. Wilfley, Stewart W Agras, Susan W Bryson
    Abstract:

    Context Interpersonal psychotherapy (IPT) is an effective specialty treatment for Binge Eating disorder (BED). Behavioral weight loss treatment (BWL) and guided self-help based on cognitive behavior therapy (CBTgsh) have both resulted in short-term reductions in Binge Eating in obese patients with BED. Objective To test whether patients with BED require specialty therapy beyond BWL and whether IPT is more effective than either BWL or CBTgsh in patients with a high negative affect during a 2-year follow-up. Design Randomized, active control efficacy trial. Setting University outpatient clinics. Participants Two hundred five women and men with a body mass index between 27 and 45 who met DSM-IV criteria for BED. Intervention Twenty sessions of IPT or BWL or 10 sessions of CBTgsh during 6 months. Main Outcome Measures Binge Eating assessed by the Eating Disorder Examination. Results At 2-year follow-up, both IPT and CBTgsh resulted in greater remission from Binge Eating than BWL ( P P P Conclusions Interpersonal psychotherapy and CBTgsh are significantly more effective than BWL in eliminating Binge Eating after 2 years. Guided self-help based on cognitive behavior therapy is a first-line treatment option for most patients with BED, with IPT (or full cognitive behavior therapy) used for patients with low self-esteem and high Eating disorder psychopathology. Trial Registration clinicaltrials.gov Identifier:NCT00060762